GlassScriptPhysician profile
Mowaffak Atfeh
NPI 1124215249
$13,294.93
in general payments reported to CMS, 2019-2025
28 companies · $2,307 in 2025
The $2,307 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,535 · 2020: $3,264 · 2021: $1,102 · 2022: $418 · 2023: $1,870 · 2024: $800 · 2025: $2,307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,273 · Travel and Lodging: $1,704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,272.58 |
| Travel and Lodging | $1,703.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $1,961.35 | 2019-2020 | |
| Medtronic, INC. | $1,721.84 | 2021-2025 | Corevalve Evolut R |
| Abbott Laboratories | $1,639.91 | 2019-2025 | Navitor, Cardiomems |
| Edwards Lifesciences Corporation | $1,613.04 | 2021-2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Medical Device Business Services, INC. | $1,224.64 | 2019 | |
| Janssen Pharmaceuticals, INC | $640.27 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $602.29 | 2019-2025 | Jardiance |
| Boston Scientific Corporation | $485.43 | 2020-2025 | Avvigo Guidance System, Ffr Link, General - Tachy |
| Sanofi-Aventis U.S. LLC | $451.47 | 2019-2023 | |
| Abiomed | $374.38 | 2020-2025 | Impella |
| Penumbra, INC. | $330.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $299.79 | 2019-2022 | |
| Amarin Pharma, INC. | $282.68 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $266.75 | 2019-2025 | |
| Astellas Pharma US INC | $253.72 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $232.77 | 2019-2024 | Camzyos |
| Amgen INC. | $154.15 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $134.94 | 2021-2025 | Verquvo |
| Kowa Pharmaceuticals America, INC. | $130.70 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $105.63 | 2019-2025 | Lifevest |
| Esperion Therapeutics, INC. | $100.42 | 2020-2021 | |
| Pfizer INC. | $96.23 | 2019-2023 | |
| Irhythm Technologies, INC. | $66.64 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Lundbeck LLC | $33.38 | 2019 | |
| Kestra Medical Technology Services, INC. | $32.33 | 2025 | Assure Wcd |
| Bayer Healthcare Pharmaceuticals INC. | $25.28 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $18.16 | 2023 | Inpefa |
| Inari Medical, INC. | $16.74 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mowaffak Atfeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.